Slide background

Pzifer: A Phase 1/2/3 Study to Evaluate Vaccine COVID-19

ID 12387 | | Visite: 4076 | NewsPermalink:

PF 07302048  BNT162 RNA Based COVID 19 Vaccines

A Phase 1/2/3 Study to Evaluate Vaccine COVID-19

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of sars-cov-2 rna vaccine candidates against covid-19 in healthy individuals.

Study Sponsor: BioNTech
Study Conducted By: Pfizer
Study Intervention Number: PF-07302048
Study Intervention Name: RNA-Based COVID-19 Vaccines
US IND Number: 19736
EudraCT Number: 2020-002641-42
Protocol Number: C4591001
Phase: 1/2/3

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.


Scarica questo file (C4591001 Clinical Protocol Nov. 2020.pdf)C4591001 Clinical Protocol Nov. 2020
Pfizer Nov 2020
EN1341 kB1181

Tags: Coronavirus

Articoli correlati